- BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with an Outperform rating and a price target of $50.
- The analyst writes that 4DMT’s platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs.
- BMO notes that 4D Molecular Therapeutics’ Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion opportunity.
- Also Read: HC Wainwright Creates Bullish Pitch On 4D Molecular Citing ‘Broader Systemic Potential.’
- The company’s cystic Fibrosis asset 4D-710 can be the first therapy delivering clinical effects in patients without treatment options, potentially unlocking around $3 billion opportunity.
- In cystic fibrosis, a 3-5%+ improvement in FEV1 can drive FDMT stock over 50% higher and render the stock an attractive acquisition target.
- Potential announcements around partnerships would trigger further upside.
- Price Action: FDMT shares are up 0.96% at $21.47 on the last check Monday.
CrowdStrike In Strong Position For Cyber-Security Consolidation, Says RBC Analyst
RBC Capital Markets analyst Matthew Hedberg reiterated an Outperform rating on CrowdStrike Holdings, Inc. (NASDAQ:CRWD), raising the price target to $180 from…
